|
|
Last Modified: 1/29/2008  First Published: 12/8/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV, Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
21 and under
|
|
|
|
Other
|
|
|
|
GPOH-NB2004 EU-20661, NCT00410631
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 to 75
|
|
|
|
Other
|
|
|
|
ADO-MM-PAL8 NCT00226473
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
18 to 75
|
|
|
|
Other
|
|
|
|
ASSO OE-1 EudraCT 2006-006647-31, NCT00525200
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 to 70
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
CMNa-ESO-01-2007 NCT00642239
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Supportive care, Treatment
|
|
|
|
Active
|
|
|
|
18 to 75
|
|
|
|
Other
|
|
|
|
UMCN-AKF 07.02 EudraCTnr 2007-003347-73, NCT00588835
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
97-02-12 NCT00686322
|
|
|
|
|
|
|
|
Last Modified: 10/7/2008  First Published: 12/1/1998 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
16 to 50
|
|
|
|
Other
|
|
|
|
EORTC-30983 NCT00003643
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 to 70
|
|
|
|
Other
|
|
|
|
UARK 2003-26 NCT00090493
|
|
|
|
|
|
|
|
Last Modified: 2/15/2007  First Published: 3/13/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Other, Pharmaceutical / Industry
|
|
|
|
FFCD-9902 SANOFI-FFCD-9902, LILLY-FFCD-9902, FFCD-FNCLCC-SFRO-9902, NCT00304135
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
Over 18
|
|
|
|
Other
|
|
|
|
DVC1.03-HMO-CTIL NCT00312819
|
|
|
|